Intelligent Bio Solutions (Nasdaq: INBS) Achieves Major Pre-FDA Submission Milestone, De-Risking U.S. Market Entry
Key Highlights for Investors
- INBS resolves all cybersecurity and software review items for its FDA 510(k) submission, following successful independent penetration testing.
- 510(k) package submission remains on track for the second half of 2026, targeting entry into the lucrative U.S. drug screening market.
- Addressed 100% of identified medium-risk cybersecurity vulnerabilities and reduced low-risk vulnerabilities from 11 to 2, with comprehensive risk-based justification for remaining items.
- All 19 software bill of materials (SBOM) vulnerabilities fully resolved and independently verified, aligning with FDA guidance.
- Strategic manufacturing partnership with Syrma Johari MedTech expected to deliver over 40% annual production cost savings and a projected 20 percentage point improvement in gross margins.
- Initial FDA clearance target is for codeine detection, with potential for significant expansion into broader U.S. applications.
- The U.S. drug screening market is a multi-billion-dollar annual opportunity across workplace, criminal justice, healthcare, and law enforcement sectors.
Details of the Announcement
Intelligent Bio Solutions Inc. (Nasdaq: INBS), a leading medical technology company specializing in rapid, non-invasive testing solutions, has announced a significant regulatory milestone ahead of its planned FDA 510(k) submission. The company has successfully addressed all cybersecurity and software-related review items, following comprehensive independent third-party penetration testing. This outcome marks the completion of the full remediation cycle and removes a major source of regulatory uncertainty as the company prepares its FDA submission for the second half of 2026.
In April 2026, INBS disclosed that penetration testing had identified no major vulnerabilities. Since then, the company has fully remediated all medium-risk cybersecurity issues and reduced low-risk issues from 11 to just 2, with a robust, risk-based justification confirming no impact on device safety, effectiveness, or performance. All 19 vulnerabilities in the software bill of materials (SBOM) have been resolved, with supporting documentation and system configuration meeting FDA requirements. Independent third-party verification has confirmed there are no remaining issues, materially reducing regulatory risk and enhancing the credibility of INBS’s upcoming 510(k) submission.
Potential Share Price Catalysts
- Regulatory De-Risking: The resolution of cybersecurity and software concerns is a key de-risking event, removing major obstacles that could have delayed or jeopardized FDA clearance.
- Strong Commercial Opportunity: The company’s 510(k) package targets codeine detection as the initial indication, with clearance expected to unlock access to the vast U.S. drug screening market, which spans workplace, criminal justice, pain management, law enforcement, and substance abuse treatment sectors.
- Operational and Financial Upside: INBS’s manufacturing partnership with Syrma Johari MedTech is projected to deliver more than 40% annual cost savings and around 20 percentage points of gross margin improvement, positioning the company for a scalable and profitable U.S. launch post-FDA clearance.
- Innovative Product: The Intelligent Fingerprinting Drug Screening System provides rapid, non-invasive, and hygienic drug testing using fingerprint sweat, delivering results in under ten minutes and detecting recent drug use within 16-24 hours. The system is already commercially deployed outside the U.S. in various sectors, highlighting its proven value proposition.
CEO Commentary
“This is a meaningful de-risking event for INBS and an important milestone in our progression toward planned U.S. market entry. Having completed the independent penetration study, we have now resolved all cybersecurity and software-related issues. We believe we are in a strong position as we advance through the remaining stages of the FDA review process and move toward our planned 510(k) submission in the second half of 2026,” commented Harry Simeonidis, President and CEO at Intelligent Bio Solutions.
About the Product
The Intelligent Fingerprinting Drug Screening System enables the collection of fingerprint sweat samples in seconds and delivers results in under ten minutes. Its non-invasive, hygienic process is performed at the point of collection. The technology is designed to detect recent drug use, and in other markets, is used for screening opiates, cocaine, methamphetamine, and cannabis. Its primary customer base outside the U.S. includes construction, manufacturing, engineering, transport, logistics, mining, drug treatment organizations, and coroners.
Forward-Looking Considerations for Shareholders
- The company is advancing toward a regulatory event (FDA 510(k) submission) that is often highly material for medtech firms, and any updates on the timeline or outcome of this process could significantly impact share price.
- Operational improvements and cost savings from the manufacturing partnership may provide additional upside to profitability post-clearance.
- Any delays or additional regulatory findings could pose risks, while successful clearance could unlock substantial value in the U.S. market.
Contact Information
Company Contact: [email protected]
Investor & Media Contact:
Valter Pinto, Managing Director, KCSA Strategic Communications
Phone: (212) 896-1254
Email: [email protected]
Disclaimer: This article contains forward-looking statements that involve risks and uncertainties. Actual results may differ materially from those described herein due to various factors, including those detailed in Intelligent Bio Solutions Inc.’s public filings with the U.S. Securities and Exchange Commission. This article is for informational purposes only and does not constitute investment advice. Please consult your financial advisor before making any investment decisions.
